Arrhythmogenic Right Ventricular Dysplasia: Clinical Results with Implantable Cardioverter Defibrillators

Mark S. Link, Paul J. Wang, Connor J. Haugh, Munther K. Homoud, Caroline B. Foote, Xenophon B. Costeas, N. A Mark Estes

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Arrhythmogenic right ventricular dysplasia is a clinical entity characterized by fatty infiltration of the right ventricle and left bundle morphology ventricular tachycardia occurring in young patients. The most common cause of death is tachyarrhythmic. Pharmacological and nonpharmacological therapies, including implantable cardioverter defibrillators, have been used to treat the arrhythmias. However, right ventricular endocardial leads in this population may be associated with an increased risk of perforation and suboptimal sensing and defibrillation efficacy due to the diseased right ventricle. We report on 12 patients with arrhythmogenic right ventricular dysplasia who were treated with implantable cardioverter defibrillators. The mean age was 31 ± 9 years (range 15-48). Patients presented with presyncope (5), syncope (4), or cardiac arrest (3). All patients had electrocardiographic abnormalities characteristic of the condition. During programmed electrical stimulation nine patients had sustained ventricular tachycardia, while three patients had no inducible arrhythmia. Transvenous leads were placed in nine patients. In these patients pacing thresholds were significantly higher, R-wave amplitudes were significantly lower, and defibrillation thresholds were not significantly different than in a cohort of patients without right ventricular dysplasia. There were no acute or chronic complications of right ventricular lead placement. Follow-up averaged 22 ± 13 months (range 1-45). There was one sudden death at 1 month of follow-up. Of the 12 patients, 8 have had appropriate therapy delivered by the implantable defibrillator. Six patients are currently on sotalol to reduce the frequency of implantable defibrillator discharges. In conclusion, implantable cardioverter defibrillators with nonthoracotomy leads are feasible and safe in patients with arrhythmogenic right ventricular dysplasia. The frequency of appropriate therapy is high, supporting the use of implantable cardioverter defibrillators in this population.

Original languageEnglish (US)
Pages (from-to)41-48
Number of pages8
JournalJournal of Interventional Cardiac Electrophysiology
Volume1
Issue number1
StatePublished - Dec 1 1997

Fingerprint

Arrhythmogenic Right Ventricular Dysplasia
Implantable Defibrillators
Syncope
Ventricular Tachycardia
Heart Ventricles
Cardiac Arrhythmias
Sotalol
Patient Rights
Sudden Death
Heart Arrest
Population
Electric Stimulation
Cause of Death
Therapeutics

Keywords

  • Arrhythmogenic right ventricular dysplasia
  • Implantable cardioverter defibrillator
  • Ventricular tachyarrhythmias

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Link, M. S., Wang, P. J., Haugh, C. J., Homoud, M. K., Foote, C. B., Costeas, X. B., & Estes, N. A. M. (1997). Arrhythmogenic Right Ventricular Dysplasia: Clinical Results with Implantable Cardioverter Defibrillators. Journal of Interventional Cardiac Electrophysiology, 1(1), 41-48.

Arrhythmogenic Right Ventricular Dysplasia : Clinical Results with Implantable Cardioverter Defibrillators. / Link, Mark S.; Wang, Paul J.; Haugh, Connor J.; Homoud, Munther K.; Foote, Caroline B.; Costeas, Xenophon B.; Estes, N. A Mark.

In: Journal of Interventional Cardiac Electrophysiology, Vol. 1, No. 1, 01.12.1997, p. 41-48.

Research output: Contribution to journalArticle

Link, Mark S. ; Wang, Paul J. ; Haugh, Connor J. ; Homoud, Munther K. ; Foote, Caroline B. ; Costeas, Xenophon B. ; Estes, N. A Mark. / Arrhythmogenic Right Ventricular Dysplasia : Clinical Results with Implantable Cardioverter Defibrillators. In: Journal of Interventional Cardiac Electrophysiology. 1997 ; Vol. 1, No. 1. pp. 41-48.
@article{9379f88d23b9444e8e189fec8d2e52c7,
title = "Arrhythmogenic Right Ventricular Dysplasia: Clinical Results with Implantable Cardioverter Defibrillators",
abstract = "Arrhythmogenic right ventricular dysplasia is a clinical entity characterized by fatty infiltration of the right ventricle and left bundle morphology ventricular tachycardia occurring in young patients. The most common cause of death is tachyarrhythmic. Pharmacological and nonpharmacological therapies, including implantable cardioverter defibrillators, have been used to treat the arrhythmias. However, right ventricular endocardial leads in this population may be associated with an increased risk of perforation and suboptimal sensing and defibrillation efficacy due to the diseased right ventricle. We report on 12 patients with arrhythmogenic right ventricular dysplasia who were treated with implantable cardioverter defibrillators. The mean age was 31 ± 9 years (range 15-48). Patients presented with presyncope (5), syncope (4), or cardiac arrest (3). All patients had electrocardiographic abnormalities characteristic of the condition. During programmed electrical stimulation nine patients had sustained ventricular tachycardia, while three patients had no inducible arrhythmia. Transvenous leads were placed in nine patients. In these patients pacing thresholds were significantly higher, R-wave amplitudes were significantly lower, and defibrillation thresholds were not significantly different than in a cohort of patients without right ventricular dysplasia. There were no acute or chronic complications of right ventricular lead placement. Follow-up averaged 22 ± 13 months (range 1-45). There was one sudden death at 1 month of follow-up. Of the 12 patients, 8 have had appropriate therapy delivered by the implantable defibrillator. Six patients are currently on sotalol to reduce the frequency of implantable defibrillator discharges. In conclusion, implantable cardioverter defibrillators with nonthoracotomy leads are feasible and safe in patients with arrhythmogenic right ventricular dysplasia. The frequency of appropriate therapy is high, supporting the use of implantable cardioverter defibrillators in this population.",
keywords = "Arrhythmogenic right ventricular dysplasia, Implantable cardioverter defibrillator, Ventricular tachyarrhythmias",
author = "Link, {Mark S.} and Wang, {Paul J.} and Haugh, {Connor J.} and Homoud, {Munther K.} and Foote, {Caroline B.} and Costeas, {Xenophon B.} and Estes, {N. A Mark}",
year = "1997",
month = "12",
day = "1",
language = "English (US)",
volume = "1",
pages = "41--48",
journal = "Journal of Interventional Cardiac Electrophysiology",
issn = "1383-875X",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Arrhythmogenic Right Ventricular Dysplasia

T2 - Clinical Results with Implantable Cardioverter Defibrillators

AU - Link, Mark S.

AU - Wang, Paul J.

AU - Haugh, Connor J.

AU - Homoud, Munther K.

AU - Foote, Caroline B.

AU - Costeas, Xenophon B.

AU - Estes, N. A Mark

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Arrhythmogenic right ventricular dysplasia is a clinical entity characterized by fatty infiltration of the right ventricle and left bundle morphology ventricular tachycardia occurring in young patients. The most common cause of death is tachyarrhythmic. Pharmacological and nonpharmacological therapies, including implantable cardioverter defibrillators, have been used to treat the arrhythmias. However, right ventricular endocardial leads in this population may be associated with an increased risk of perforation and suboptimal sensing and defibrillation efficacy due to the diseased right ventricle. We report on 12 patients with arrhythmogenic right ventricular dysplasia who were treated with implantable cardioverter defibrillators. The mean age was 31 ± 9 years (range 15-48). Patients presented with presyncope (5), syncope (4), or cardiac arrest (3). All patients had electrocardiographic abnormalities characteristic of the condition. During programmed electrical stimulation nine patients had sustained ventricular tachycardia, while three patients had no inducible arrhythmia. Transvenous leads were placed in nine patients. In these patients pacing thresholds were significantly higher, R-wave amplitudes were significantly lower, and defibrillation thresholds were not significantly different than in a cohort of patients without right ventricular dysplasia. There were no acute or chronic complications of right ventricular lead placement. Follow-up averaged 22 ± 13 months (range 1-45). There was one sudden death at 1 month of follow-up. Of the 12 patients, 8 have had appropriate therapy delivered by the implantable defibrillator. Six patients are currently on sotalol to reduce the frequency of implantable defibrillator discharges. In conclusion, implantable cardioverter defibrillators with nonthoracotomy leads are feasible and safe in patients with arrhythmogenic right ventricular dysplasia. The frequency of appropriate therapy is high, supporting the use of implantable cardioverter defibrillators in this population.

AB - Arrhythmogenic right ventricular dysplasia is a clinical entity characterized by fatty infiltration of the right ventricle and left bundle morphology ventricular tachycardia occurring in young patients. The most common cause of death is tachyarrhythmic. Pharmacological and nonpharmacological therapies, including implantable cardioverter defibrillators, have been used to treat the arrhythmias. However, right ventricular endocardial leads in this population may be associated with an increased risk of perforation and suboptimal sensing and defibrillation efficacy due to the diseased right ventricle. We report on 12 patients with arrhythmogenic right ventricular dysplasia who were treated with implantable cardioverter defibrillators. The mean age was 31 ± 9 years (range 15-48). Patients presented with presyncope (5), syncope (4), or cardiac arrest (3). All patients had electrocardiographic abnormalities characteristic of the condition. During programmed electrical stimulation nine patients had sustained ventricular tachycardia, while three patients had no inducible arrhythmia. Transvenous leads were placed in nine patients. In these patients pacing thresholds were significantly higher, R-wave amplitudes were significantly lower, and defibrillation thresholds were not significantly different than in a cohort of patients without right ventricular dysplasia. There were no acute or chronic complications of right ventricular lead placement. Follow-up averaged 22 ± 13 months (range 1-45). There was one sudden death at 1 month of follow-up. Of the 12 patients, 8 have had appropriate therapy delivered by the implantable defibrillator. Six patients are currently on sotalol to reduce the frequency of implantable defibrillator discharges. In conclusion, implantable cardioverter defibrillators with nonthoracotomy leads are feasible and safe in patients with arrhythmogenic right ventricular dysplasia. The frequency of appropriate therapy is high, supporting the use of implantable cardioverter defibrillators in this population.

KW - Arrhythmogenic right ventricular dysplasia

KW - Implantable cardioverter defibrillator

KW - Ventricular tachyarrhythmias

UR - http://www.scopus.com/inward/record.url?scp=0031061181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031061181&partnerID=8YFLogxK

M3 - Article

C2 - 9869950

AN - SCOPUS:0031061181

VL - 1

SP - 41

EP - 48

JO - Journal of Interventional Cardiac Electrophysiology

JF - Journal of Interventional Cardiac Electrophysiology

SN - 1383-875X

IS - 1

ER -